GlaxoSmithKline – Sales Tick Up And GSK Finally Enters The Covid Fray, But Still A Mixed Bag

0
GlaxoSmithKline – Sales Tick Up And GSK Finally Enters The Covid Fray, But Still A Mixed Bag
3844328 / Pixabay

GlaxoSmithKline (LON:GSK) reported second quarter sales of £8.1bn, up 15% at constant exchange rates (CER). That reflects particularly strong growth in Pharmaceuticals and Vaccines businesses.

Get The Full Warren Buffett Series in PDF

Get the entire 10-part series on Warren Buffett in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues

Q2 2021 hedge fund letters, conferences and more

Underlying operating profits rose 43% to £2.2bn as the group benefited from a weaker comparator, due to de-stocking in both pharmaceuticals and consumer healthcare in the same period last year, and ongoing cost savings.

SALT New York: Canyon, Mudrick, Fortress And Sculptor On Finding Distressed Value

At the 2021 SALT New York conference, which was held earlier this week, one of the panels on the main stage discussed the best macro shifts coming out of the pandemic and investing in value amid distress. The panel featured: Todd Lemkin, the chief investment officer of Canyon Partners; Peter Wallach, the managing director and Read More

The group announced a dividend of 19p per share for the quarter and continues to expect full year dividends to hit 80p.

GSK shares rose 2.7% following the announcement.

GSK's Vaccine Sales Are Ramping Up

Nicholas Hyett, Equity Analyst at Hargreaves Lansdown:

“The fact AstraZeneca beat GSK to a coronavirus vaccine has been a source of some discontent at the UK’s largest vaccine manufacturer. This quarter the group has finally started to put that right. Sales of its vaccine adjuvant, which helps enhance the immune response, are ramping up and a Covid treatment is also hitting pharmacies. It’s part of wider good news for GSK, which has seen sales of its newer drugs gather pace this quarter, helped by favourable comparators last year. Those increased sales have fed quickly though to the bottom line, boosting underlying profits.

However, despite what is definitely progress we think GSK’s long term challenges remain unresolved. There may be more flesh on the bones of the planned Consumer Goods demerger following June’s investor update, but the group is still in limbo waiting for the separation to actually happen.

More pressing is the still very poor levels of cash generation. Free cash flow in the first half of the year hasn’t come anywhere near covering the dividend, and as a result debt continues to mount. A dividend cut after the demerger will ease some of the pressure, as will the sale of some shares in the consumer business, but it’s yet another example of investors being promised jam tomorrow when previous promises have been rather disappointing.”


About Hargreaves Lansdown

Over 1.6 million clients trust us with £132.9 billion (as at 30 April 2021), making us the UK’s largest digital wealth management service. More than 98% of client activity is done through our digital channels and over 600,000 access our mobile app each month.

Updated on

Previous article Boeing Reports Profit For The First Time in Almost Two Years
Next article Dan Celia: Political Agendas Effect Inflation
Jacob Wolinsky is the founder of ValueWalk.com, a popular value investing and hedge fund focused investment website. Jacob worked as an equity analyst first at a micro-cap focused private equity firm, followed by a stint at a smid cap focused research shop. Jacob lives with his wife and four kids in Passaic NJ. - Email: jacob(at)valuewalk.com - Twitter username: JacobWolinsky - Full Disclosure: I do not purchase any equities anymore to avoid even the appearance of a conflict of interest and because at times I may receive grey areas of insider information. I have a few existing holdings from years ago, but I have sold off most of the equities and now only purchase mutual funds and some ETFs. I also own a few grams of Gold and Silver

No posts to display